Zhu J, Ma J, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology(CSCO)diagnosis and treatment guidelines for malignant lymphoma 2021(English version)[J]. Chin J Cancer Res, 2021, 33(3): 289-301. doi: 10.21147/j.issn.1000-9604.2021.03.01

Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019[J]. Aging(Albany NY), 2022, 14(7): 3175-3190.

Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma[J]. Lancet, 2017, 390(10091): 298-310. doi: 10.1016/S0140-6736(16)32407-2

Connors JM, Cozen W, Steidl C, et al. Hodgkin lymphoma[J]. Nat Rev Dis Primers, 2020, 6(1): 61. doi: 10.1038/s41572-020-0189-6

Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia[J]. J Clin Oncol, 2005, 23(22): 5027-5033. doi: 10.1200/JCO.2005.09.137

Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J]. Blood, 2010, 116(12): 2040-2045. doi: 10.1182/blood-2010-03-276246

Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type Ⅱ CD20 antibody GA101(obinutuzumab)compared with rituximab and ofatumumab in vitro and in xenograft models[J]. Mol Cancer Ther, 2013, 12(10): 2031-2042. doi: 10.1158/1535-7163.MCT-12-1182

Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type Ⅱ anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity[J]. Blood, 2010, 115(22): 4393-4402. doi: 10.1182/blood-2009-06-225979

Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma[J]. N Engl J Med, 2017, 377(14): 1331-1344. doi: 10.1056/NEJMoa1614598

Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety[J]. J Clin Oncol, 2018, 36(23): 2395-2404. doi: 10.1200/JCO.2017.76.8960

Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394(10200): 793-804. doi: 10.1016/S0140-6736(19)31774-X

Straus DJ, Dlugosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stage Ⅲ/Ⅳ classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study[J]. Blood, 2020, 135(10): 735-742. doi: 10.1182/blood.2019003127

Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase Ⅲ study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma[J]. Ann Oncol, 2022, 33(3): 288-298. doi: 10.1016/j.annonc.2021.12.002

Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2022, 386(4): 351-363. doi: 10.1056/NEJMoa2115304

Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma(LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 790-800. doi: 10.1016/S1470-2045(21)00139-X

Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline[J]. Nat Rev Drug Discov, 2019, 18(8): 585-608. doi: 10.1038/s41573-019-0028-1

Newman MJ, Benani DJ. A review of blinatumomab, a novel immunotherapy[J]. J Oncol Pharm Pract, 2016, 22(4): 639-645. doi: 10.1177/1078155215618770

Goebeler ME, Bargou R. Blinatumomab: a CD19/CD3 bispecific T cell engager(BiTE)with unique anti-tumor efficacy[J]. Leuk Lymphoma, 2016, 57(5): 1021-1032. doi: 10.3109/10428194.2016.1161185

Budde LE, Assouline S, Sehn LH, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase Ⅰ Dose-Escalation Study[J]. J Clin Oncol, 2022, 40(5): 481-491. doi: 10.1200/JCO.21.00931

Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase Ⅰ Trial[J]. J Clin Oncol, 2021, 39(18): 1959-1970. doi: 10.1200/JCO.20.03175

Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma[J]. N Engl J Med, 2022, 386(7): 640-654. doi: 10.1056/NEJMoa2116133

Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma[J]. N Engl J Med, 2022, 386(7): 629-639. doi: 10.1056/NEJMoa2116596

Zhitao Ying. 2-Year Follow-up Results of RELIANCE Study, a Multicenter Phase 2 Trial of Relmacabtagene Autoleucel(Carteyva)in Chinese Patients with Relapsed/Refractory Large B-cell Lymphoma[C]. 2022, ASCO poster.

Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies(BRUIN): a phase 1/2 study[J]. Lancet, 2021, 397(10277): 892-901. doi: 10.1016/S0140-6736(21)00224-5

Song Y, Liu Y, Li ZM, et al. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, phase 1, dose-escalation, dose-expansion and clinical expansion study[J]. Lancet Haematol, 2022, 9(7): e493-e503. doi: 10.1016/S2352-3026(22)00134-X

Matasar MJ, Capra M, Ozcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma(CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(5): 678-689. doi: 10.1016/S1470-2045(21)00145-5

Liu W, Ping L, Xie Y, et al. A phase Ⅰ pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma[J]. Cancer Chemother Pharmacol, 2022, 89(6): 825-831. doi: 10.1007/s00280-022-04417-3